Study of Anginera in Adults With a Left Ventricular Assist Device (LVAD) as Bridge to Transplant

Status unconfirmed · Phase 1

Conditions studied: Heart Failure

In brief

The purpose of this study is to obtain human heart tissue after treatment with Anginera to determine its effect on a variety of things that might indicate improvement in heart function. Patients who will have a left ventricular assist device (LVAD) implanted while they wait for a donated heart will be treated with Anginera. At the time of heart transplant, their diseased heart which is removed will be analyzed by microscopic examination to see what effect Anginera had.

Key facts

Study ID

NCT00364598

Run by

Theregen, Inc.

People needed

15

Starts

2006-12-01

Expected to finish

2009-02-01

Last updated by the study team

2009-03-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Stage D Heart Failure
• Patients having an LVAD implanted as a bridge to transplant.

You may not qualify if…

• Biopsy proven acute myocarditis
• Known Giant Cell Myocarditis
• Known infiltrative disease, e.g. cardiac Amyloidosis, Sarcoidosis, hemochromatosis, Fabry's Disease

Where it is running

• Yale University School of Medicine — New Haven, Connecticut, United States
• University of Maryland School of Medicine — Baltimore, Maryland, United States
• University of Pennsylvania School of Medicine — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.